Who's next to leave?

Discussion in 'Lundbeck' started by anonymous, Jul 27, 2017 at 12:56 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    You are 1000% right! Staffen's leaving is far more significant than Kare leaving. He had to know Kare was leaving, so why didn't he try and cut a deal for the CEO position, unless he knew there was a good chance there would be NO CEO position available, say due to a sell of the company or a return to their old model of licensing products out. Nobody in the U.S. is capable of the CEO role. No, both of them would have to feel there is no future at Lundbeck, and they are right.
     

  2. anonymous

    anonymous Guest

    Come on...let's dial down the drama a bit. Not saying this isn't an ominous sign, but in reality, Lundbeck will still continue to exist and still have a number of people working for them. So the doors will not be locked, paychecks will come in, etc.

    I think that this means that they saw Teva and a privately held company as more desirable destinations with greater prospects than Lundbeck. That I think does say a lot. Teva is in rebuilding and had lost their biggest product's exclusivity. So he is playing with house money at this point...only direction really is up for that company and it's a big BIG company...not like Lundbeck. So he saw an opportunity to leave when Lundbeck was going to go through a lull (which may be seen as his fault...and I don't fully disagree) and go to a bigger company and play with the big boys. It's like playing in the minor leagues where you know you're going to lose talent and then getting to coach the worst team in the big leagues. In the end, it's still the big leagues.

    For Staffan, that one confuses me. I agree that there can't be any way that he didn't know that Kare was going to leave...maybe it was only for a week as they were putting the press release together, but still, that's enough time for the board to have taken action and say, "stay Staffan...you'll be CEO" and to think he probably still said "No"...that's probably most telling. Maybe too many things are broken? Maybe the lull is worse than we think? Who knows, but ultimately, these two who have full view of the organization and the future made the choice to leave because prospects were greater elsewhere. Not encouraging...
     
  3. anonymous

    anonymous Guest

    Staffan leaving will send a message to all talented senior execs->the future here sucks. Once the stock tanks, do not be surprised if the foundation divests a bunch of the company.

    The story here has been the same as the last 12 months. Without Idalopirdine and a cognition label for Trin, we have nothing to replace Xenazine, Sabril, and Onfi sales. Leadership just fed BS to try to keep sales up.
     
  4. anonymous

    anonymous Guest

    I don't see any announcement in my email
     
  5. anonymous

    anonymous Guest

    I'll be at home during today's conference call putting the finishing touches on my resume. Fuck this shit. I have no more room for optimism.

    - "A formerly optimistic employee"
     
  6. anonymous

    anonymous Guest

    no email just a conf call this afternoon
     
  7. anonymous

    anonymous Guest

    now I know that Cafepharma is not exactly a forum for real thought-provoking ideas bit what if Staffan left because he was not going to be offered the CEO position? Not time to light your hair on fire just yet.
     
  8. anonymous

    anonymous Guest

    It's all over the internet! Easy to find. Go to Fiercepharma.com.
     
  9. anonymous

    anonymous Guest

    Either way it's a huge vote of no confidence from the biggest internal stakeholder besides Kare.

    Kare probably finally leveled with him and told him exactly what to expect over the next 2-5 years and Staffan called the first recruiter he could find.
     
  10. anonymous

    anonymous Guest

    the product director for Turdthera should be nervous. Everyone that bought this POS is now gone and she has been with it since day one. When they go looking for scapegoats, she is going to get tossed by others trying to distance themselves from this debacle.
     
  11. anonymous

    anonymous Guest

    kim admits that she wants to change the way northera is available. unfortunately she said that senior management makes the calls on how we sell it and access. she admitted "greed" is why they will not change. this drug per chelsea prior to our overpaying for it was to launch at a 30/day price, similar to onfi.

    its now 300+/day. yes lundbeck is adding to the problem of expensive healthcare. no drug for reducing dizzy symptoms should cost a house in a year.

    the people up top are the problem, not kim. kim is basically in a position of no say and lets be real, what positive has come of launching this drug. now they want to roll out 2 year old profiles they paid for. more bs to give spin to the company about how great this is. pillars of shit is what it is
     
  12. anonymous

    anonymous Guest

    Dan B is the one who wanted to price Northera crazy high. He was also the driving force behind us acquiring it.
     
  13. anonymous

    anonymous Guest

    dan was the driving force on the acquisition from baylor down in texas with former account manager now area manager being in the mix. wonder how many insider stock trades happened on that deal with reps buying on the rumor mill and haven't yet been investigated for the windfall price increase of chelsea on the news
     
  14. anonymous

    anonymous Guest

    Doesn't sound like she has much clout, more like a product manager than product director. Guess they needed to keep someone around to do profiles.
     
  15. anonymous

    anonymous Guest

    I’ve read this five times and understand it less every time.
     
  16. anonymous

    anonymous Guest

    Medicare patients no longer getting grant support for Northera?? This cant be true!
     
  17. anonymous

    anonymous Guest

    Well since this thread is "Who is next to leave" maybe the patient is next to leave. If this is true we are more then F***ed
     
  18. anonymous

    anonymous Guest

    the recruiters are calling and more companies see this upside down whale in the ocean just being feasted on by the sharks

    such a great story that turned into a greed moron show by the senior management

    fuck their goals and bullshit mg game, they have no data to suggest anything more than hospital titration and somehow 300mg is a real script. way to motivate your people to get patients started and way to go to charge insane money for a drug that helps being less dizzy

    the black eye is coming for this company
     
  19. anonymous

    anonymous Guest

    She's a hack that talks out of both sides of her mouth. Tells management. What they want to hear and everyone else a different song.
     
  20. anonymous

    anonymous Guest

    I second this. I've spoken to her at meetings before and she has promised to look into certain things. But I hear she just bends to the will of Amy Magro and Lorena all the time. Don't waste your breath talking to her or providing her feedback. You'll just end up on management's radar because Kim Glisson is just a spy for them.